Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
MATURE-HEPATOCYTE TRANSDIFFERENTIATION SUPPRESSING COMPOSITION
Document Type and Number:
WIPO Patent Application WO/2023/026794
Kind Code:
A1
Abstract:
[Problem] To provide: a composition that suppresses mature-hepatocyte transdifferentiation or a composition that is capable of treating cholangiocarcinoma; and a screening method for substances for suppressing mature-hepatocyte transdifferentiation or substances for treating cholangiocarcinoma. [Solution] The present invention provides a composition that contains NF-κB inducing kinase inhibitor (NIK inhibitor) and that suppresses mature-hepatocyte transdifferentiation or a composition for treating cholangiocarcinoma. In addition, the present invention provides a screening method for substances for suppressing mature-hepatocyte transdifferentiation or substances for treating cholangiocarcinoma, the method including a step for measuring the activity of NF-κB inducing kinase. The composition of the present invention improves the regulatory dysfunction of the TRAF3-NIK axis involved in mature-hepatocyte transdifferentiation and development and exacerbation of cholangiocarcinoma.

Inventors:
KODAMA TAKAHIRO (JP)
SHIODE YUTO (JP)
TAKEHARA TETSUO (JP)
Application Number:
PCT/JP2022/029655
Publication Date:
March 02, 2023
Filing Date:
August 02, 2022
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV OSAKA (JP)
International Classes:
A61K45/00; A61K31/4439; A61K31/7088; A61K48/00; A61P1/16; A61P35/00; A61P43/00; C12Q1/06; C12Q1/48; G01N33/15; G01N33/50
Domestic Patent References:
WO2015025026A12015-02-26
WO2018037059A12018-03-01
WO2017125530A12017-07-27
Foreign References:
JP2016531127A2016-10-06
Other References:
LU W.-X.: "Long non-coding RNA MEG3 represses cholangiocarcinoma by regulating miR-361-5p/TRAF3 axis", EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, vol. 23, no. 17, 1 January 2019 (2019-01-01), pages 7356 - 7368, XP093041064, DOI: 10.26355/eurrev_201909_18842
ZHANG, S. ET AL.: "MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-kB-inducing kinase (NIK).", ONCOGENE, vol. 31, November 2011 (2011-11-01), pages 3607 - 3620, XP037749799, DOI: doi.org/10.1038/onc.2011.523
LI BO-AN: "A novel tumor suppressor miRNA miR-520e contributes to suppression of hepatoma", ACTA PHARMACOLOGICA SINICA, NATURE PUBLISHING GROUP, GB, vol. 33, no. 1, 1 January 2012 (2012-01-01), GB , pages 3 - 4, XP093041063, ISSN: 1671-4083, DOI: 10.1038/aps.2011.198
YUTO SHIODE; TAKAHIRO KODAMA; HAYATO HIKITA; RYOTARO SAKAMORI; TOMOHIDE TATSUMI; TETSUO TAKEHARA: "Inactivation of traf3 promotes intrahepatic cholangiocarcinoma development via hepatocyte trans-differentiation.", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 81, no. 13_Supplement, 1 July 2021 (2021-07-01) - 21 May 2021 (2021-05-21), US , XP009543932, ISSN: 1538-7445, DOI: 10.1158/1538-7445.AM2021-2927
SHIODE YUTO, KODAMA TAKAHIRO, SHIGENO SATOSHI, MURAI KAZUHIRO, TANAKA SATOSHI, NEWBERG JUSTIN Y., KONDO JUMPEI, KOBAYASHI SHOGO, Y: "TNF receptor–related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF‐κB‐inducing kinase–mediated hepatocyte transdifferentiation", HEPATOLOGY, JOHN WILEY & SONS, INC., US, vol. 77, no. 2, 1 February 2023 (2023-02-01), US , pages 395 - 410, XP093041061, ISSN: 0270-9139, DOI: 10.1002/hep.32317
RIZVI S ET AL., NAT REV CLIN ONCOL., vol. 15, no. 2, 2018, pages 95 - 111
BANALES JM ET AL., NAT REV GASTROENTEROL HEPATOL, vol. 17, no. 9, 2020, pages 557 - 88
FARSHIDFAR F ET AL., CELL REP., vol. 19, no. 13, 2017, pages 2878 - 80
KODAMA T ET AL., GASTROENTEROLOGY, vol. 151, no. 2, 2016, pages 324 - 37
KODAMA T ET AL., PROC NATL ACAD SCI U S A., vol. 113, no. 24, 2016, pages E3384 - 93
SHIODE YUTO ET AL., THE 57TH ANNUAL MEETING OF THE JAPAN SOCIETY OF HEPATOLOGY, 2021, pages WS9 - 10
BRIGHTBILL HD ET AL., NAT COMMUN, vol. 9, no. 1, 2018, pages 179
NISHIKAWA ET AL., THE 109TH ANNUAL MEETING OF THE JAPANESE SOCIETY OF PATHOLOGY
SCHULER M ET AL., GENESIS, vol. 39, no. 3, 2004, pages 167 - 172
KODAMA T ET AL., PROC NATL ACAD SCI USA., vol. 115, no. 44, 2018, pages E10417 - E10426
HASEGAWA M ET AL., BIOCHEM BIOPHYS RES COMMUN., vol. 405, no. 3, 2011, pages 405 - 410
MURAI K ET AL., SCI REP, vol. 10, no. 1, 2020, pages 941
BROUTIER L ET AL., NAT PROTOC., vol. 11, no. 9, 2016, pages 1724 - 1743
TANAKA S ET AL., HEPATOLOGY, vol. 64, no. 6, 2016, pages 1994 - 2014
HORIE Y ET AL., J CLIN INVEST, vol. 113, no. 12, 2004, pages 1774 - 1783
MANN KM ET AL., NAT BIOTECHNOL., vol. 34, no. 9, 2016, pages 962 - 972
SORIANO P, NAT GENET., vol. 21, no. 1, 1999, pages 70 - 71
YANGER K ET AL., CELL STEM CELL, vol. 15, no. 3, 2014, pages 340 - 349
SEEHAWER M ET AL., NATURE, vol. 562, no. 7725, 2018, pages 69 - 75
PARVATIYAR K ET AL., NAT COMMUN., vol. 9, no. 1, 2018, pages 2770
Attorney, Agent or Firm:
SHOJI Takashi et al. (JP)
Download PDF: